SUPPLY CHAIN
Cryoport | August 28, 2021
Cryoport, Inc., a leading global provider of innovative temperature-controlled supply chain solutions to the life sciences including clinical research, pharmaceutical and cell and gene therapy markets, and Mitsubishi Logistics Corporation ("MLC"), Japan's leading pharma logistics company, today announced a multi-year strategic business alliance to create an integrated regenerative medicine supply chain partnership in Japan.
Cryoport and MLC will partner to create synergistic value by leveraging each other's global logistics networks. The partnership will provide integrated, end-to-end distribution solutions for specialty cell and gene therapies that demand stringent temperature control, track and trace systems and global distribution. MLC has chosen to adopt Cryoport's unique and proprietary temperature-controlled and traceability solutions to meet the increasing demand for cell and gene therapy supply chain solutions and to strengthen its logistics capabilities.
Mr. Masao Fujikura, President of MLC said, "This strategic alliance will strengthen our ultra-low temperature-logistics services for our valued customers both domestically and internationally, utilizing Cryoport's proprietary technologies for cell and gene materials."
Jerrell Shelton, CEO of Cryoport, said, "This strategic alliance furthers our expansion strategy in the Asia-Pacific ("APAC") region. MLC and Cryoport will encourage the use of each other's network, infrastructure, knowledge and resources to enhance each other's operational performance and to generate value for customers in Japan and overseas to meet demand from the increasing number of cell and gene therapies currently in development and expected to launch in coming years. Combining both companies' strengths is expected to realize reliable and seamless distribution services for biopharmaceutical and pharmaceutical companies in Japan and the APAC region."
As of June 30, 2021, Cryoport supported 561 clinical trials in regenerative medicine globally, 29 of which are in the APAC region. In addition, a number of therapies supported by Cryoport have recently been approved in the APAC region, including Novartis' commercial therapy KYMRIAH®, which is approved in Japan, Singapore and Australia and Bristol Myers Squibb's commercial therapy BREYANZI®, which was approved in Japan. Cryoport is continuing to build out its position to support the growing number of commercial therapies in anticipation of the next wave of expected commercial approvals in the APAC region.
About Cryoport, Inc.
Cryoport, Inc. is redefining temperature-controlled supply chain support for the life sciences industry by continually broadening its platform of solutions and services, serving the Biopharma, Reproductive Medicine, and Animal Health markets. Through its family of companies, Cryoport Systems, MVE Biological Solutions, CRYOPDP and CRYOGENE, Cryoport provides strategic solutions that support the growing needs of these markets. Cryoport's mission is to support life and health on earth through its advanced technologies, global supply chain network and dedicated scientists, technicians and supporting teams of professionals. Cryoport serves clients in life sciences research, clinical trials, and product commercialization.
Read More
SUPPLY CHAIN
Visionet | January 20, 2022
Visionet Systems, the leader in digitally enabled solutions for businesses around the world, is evolving PartnerLinQ, its flagship digital supply chain connectivity solution, to push the boundaries of connectivity by simplifying visibility and connectivity across the global supply chain and commerce channels. With PartnerLinQ's new capabilities, customers can access its native app ecosystem allowing users to add more business context to their solution with one click.
The new digital connectivity ecosystem is built to handle the evolving state of global supply chains. With PartnerLinQ we are building a more resilient supply chain for our customers that can withstand supply chain disruptions like we've seen in the last few years,"
Ahmed Raza, VP of PartnerLinQ.
The PartnerLinQ App EcoSystem allows customers to find the app that corresponds to their partners' business model; install the app, and immediately start adding value to the partner and channel communications. The automated end-to-end workflows within the PartnerLinQ platform are built on a hybrid cloud architecture for resilient translation processing.
We are very focused on enabling agile digital connectivity through cutting edge technology for global supply chains, Our platform's mission is to help supply chain companies reduce business risk by becoming more resilient, flexible, and empowered through enhanced visibility and control."
President, Visionet Jawad Khan.
PartnerLinQ is pushing the boundaries of digital connectivity through its Message Processing Engine that connects directly with partners' ERP, OMS, WMS TMS, and MRP enterprise-level systems through a single process. The native app ecosystem offers supply chain workers and executives a chance to zero in on business issues, track them, and use that insight to address supply chain issues.
About PartnerLinQ
PartnerLinQ is an innovative, cloud-native supply chain visibility platform that delivers resilience through simplifying visibility and connectivity. PartnerLinQ's Native App Ecosystem adds business context to traditional integrations, minimizing the impact of disruption.
With capabilities for intelligent hyper-automation, multi-channel integration, and real-time analytics, PartnerLinQ seeks to seamlessly connect multi-tier supply chain networks, channels, marketplaces, and core systems worldwide to deliver unified connectivity for the future.
Read More
SOURCE | October 22, 2020
MediaMath, acclaimed independent advertising technology company for brands and agencies, continues to deliver upon the SOURCE vision to co-create an accountable, aligned, addressable ecosystem with its industry partners. The company today announced the launch of the SOURCE Ecosystem Scorecard, which provides a roadmap to drive the industry toward continued efficiency and effectiveness. "With SOURCE, we set out to address some of the biggest issues facing the industry – to create an environment that is accountable and addressable, and to align the interests of brands, agencies, publishers and technology providers," said MediaMath founder and CEO Joe Zawadzki. "The SOURCE Ecosystem Scorecard continues to make good on that promise and is truly a Holy Grail for the industry – a configurable setting that provides brands and agencies with unparalleled transparency and control, giving them confidence to direct their investments based on their express priorities across all digital channels." The SOURCE Ecosystem Scorecard, now available globally, is designed to provide unique clarity into the ecosystem supply partners that provide the most value to advertisers, ultimately empowering advertisers to make better-informed decisions about their supply path. It also acts as a technology roadmap for the betterment of both DSPs and SSPs.
Read More